



We claim:

1. A compound of formula (I), their analogs, their stereoisomers, tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, and  
 5 pharmaceutical compositions containing them.



Where Ar represents an optionally substituted phenyl ring, five or six membered hetero aromatic ring which may be substituted or unsubstituted;  $R_1$  &  $R_2$  may be same or different and represent hydrogen, halogen, substituted or unsubstituted groups selected from alkyl, aralkyl, alkoxy, thio, amino, aminoalkyl, nitro, cyano, formyl, thioalkoxy, cycloalkyl, haloalkyl, haloalkoxy, groups;  
 10


Y represents the groups  $G_1$ ,  $G_2$  or  $G_3$ :



where  $R_3$  &  $R_4$  may be same or different and represent H,  $C_1$ - $C_6$  substituted or  
 15 unsubstituted linear or branched alkyl group, halogen, hydroxy, cyano, haloalkyl, haloalkoxy, perhaloalkoxy, thio, substituted or unsubstituted groups selected from cycloalkyl,  $(C_1$ - $C_{12})$ alkoxy, cyclo $(C_3$ - $C_7)$ alkoxy, aryl, aryloxy, aralkyl, ar $(C_1$ - $C_{12})$ alkoxy, acyl, acyloxy, carboxylic acid and its derivatives such as esters and amides, hydroxyalkyl, aminoalkyl, mono-substituted or di-substituted aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl,  $(C_1$ - $C_{12})$ alkylthio, thio $(C_1$ - $C_{12})$ alkyl & arylthio; X represents  
 20 O, S or  $NR^5$  where  $R^5$  represents H or (un)substituted alkyl or aryl groups; A represents a (un)substituted, saturated or unsaturated or partially saturated single or fused ring moiety, optionally containing one or more heteroatoms selected from N, S, O; Z represents H,  $C_1$ - $C_6$  substituted or unsubstituted alkyl group, cyano, haloalkyl,

haloalkoxy, perhaloalkoxy, substituted or unsubstituted groups selected from cycloalkyl, bicycloalkyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxy, cyclo(C<sub>3</sub>-C<sub>7</sub>)alkoxy, aryl, aryloxy, aralkyl, ar(C<sub>1</sub>-C<sub>12</sub>)alkoxy, heterocyclyl, heteroaryl, heterocyclyl(C<sub>1</sub>-C<sub>12</sub>)alkyl, heteroar(C<sub>1</sub>-C<sub>12</sub>)alkyl, heteroaryloxy, heteroar(C<sub>1</sub>-C<sub>12</sub>)alkoxy, heterocycloxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, carboxylic acid and its derivatives such as esters and amides, hydroxyalkyl, aminoalkyl, mono-substituted or di-substituted aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, (C<sub>1</sub>-C<sub>12</sub>)alkylthio, thio(C<sub>1</sub>-C<sub>12</sub>)alkyl, arylthio, SO<sub>2</sub>R<sub>6</sub> and SO<sub>2</sub>R<sub>6</sub>, where R<sub>6</sub> represents amino, optionally substituted groups selected from alkyl, aryl, heteroaryl, heterocyclyl groups; the dotted line '-----' represents either a bond or a no bond.

W represents OH, N<sub>3</sub>, NH<sub>2</sub>, NCS, OSO<sub>2</sub>CH<sub>3</sub> or a moiety of general formula



Wherein R<sub>7</sub> may be H, substituted or unsubstituted groups selected from amino, alkylamino, dialkylamino, aralkylamino, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>12</sub>alkyl, aralkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>1</sub>-C<sub>6</sub>thioalkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, thioalkoxy, and X is selected from O, S, -NR<sub>5</sub> where R<sub>5</sub> represents H, or substituted or unsubstituted alkyl group or aryl groups.

2. A compound as defined in claim 1 wherein substituents on groups A & Z are selected from cyano, nitro, halo, perhaloalkyl, carboxyl, hydrazino, azido, formyl, amino, thio, hydroxy, sulfonyl, or substituted or unsubstituted groups selected from alkyl which may be linear or branched; cycloalkyl, alkenyl, cycloalkenyl, alkynyl, hydrazinoalkyl, alkylhydrazido, hydroxylamino, acyl, acyloxy, acylamino, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylaminoalkyl, arylamino, alkylamino, aralkylamino, aralkoxy, haloaralkyl, aralkenyl, aryl, aralkyl, aryloxy, alkoxy, alkylcarbonyl, alkoxycarbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkylcarbonylalkyl, alkoxy carbonylalkyl, 1-alkoxy carbonyloxy-alkyl, 1-cycloalkyloxy carbonyloxy-alkyl, carboxamidoalkyl, cyanoamidino, cyanoalkyl, aminocarbonylalkyl, N-aminocarbonylalkyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, carboxyalkylaminocarboxy, N-

alkylamino, N,N-dialkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-aralkyl-N-alkylaminoalkyl, N-alkyl-N-arylaminoalkyl, N,N-dialkylaminocarbonyl, N-alkyl-N-arylaminoalkyl, N-alkyl-N-hydroxyaminocarbonyl, N-alkyl-N-hydroxyaminocarbonylalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, arylthio, aralkylthio, alkoxycarbonyl, aminocarbonyl, alkoxycarbonylamino, cycloalkyl, bicycloalkyl, cycloalkoxy, bicycloalkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, heterocycloalkoxycarbonyl, heteroaryloxy carbonyl, heteroaralkoxycarbonyl, RSO<sub>2</sub>NH- and RSO<sub>2</sub>O- groups wherein R represents alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl groups.

3. A compound as claimed in claim 1 where R<sup>1</sup> is hydrogen and R<sup>2</sup> is halo.

4. A compound as claimed in **claim 1** where Ar represents a phenyl ring.

5. A composition comprising a compound of formula (I), or a therapeutically acceptable salt or prodrug thereof, and a therapeutically acceptable excipient.

6. A pharmaceutical composition according to claim 6, in the form of a tablet, capsule, powder, granules, syrup, solution or suspension

7. A method for treating bacterial infections, psoriasis, arthritis in mammals comprising administering a therapeutically acceptable amount of compound of formula (I), or a therapeutically acceptable salt or prodrug thereof.

8. The method as claimed in **claim 7** wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.

9. A method for treating toxicity due to chemotherapy in a patient comprising administering a therapeutically acceptable amount of compound of formula (I), or a therapeutically acceptable salt or prodrug thereof.

10. The method as claimed in **claim 9** wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.

11. A compound according to **claim 1** which is selected from :

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-hydroxyphenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-hydroxyphenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-hydroxyphenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl ]thiourea;

- (S)-N-[3-(3-Fluoro-4-{4-[3-(3-hydroxyphenyl)-acryloyl]-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(3-hydroxyphenyl)-acryloyl]-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- 5 (S)-N-[3-{4-(4-(3-Benzo[1,3]-dioxol-5-yl-acryloyl)-piperazin-1-yl}-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-{4-(4-(3-Benzo[1,3]-dioxol-5-yl-acryloyl)-piperazin-1-yl}-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- (S)-N-[3-{4-(4-(3-Benzo[1,3]-dioxol-5-yl-acryloyl)-piperazin-1-yl}-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl] thiourea;
- 10 (S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-3-yl)-acryloyl]-piperazinyl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-2-yl)-acryloyl]-piperazinyl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 15 (S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-2-yl)-acryloyl]-piperazinyl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-2-yl)-acryloyl]-piperazinyl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thiourea;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-2-yl)-acryloyl]-piperazinyl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thiocarbamate;
- 20 (S)-N-[3-(3-Fluoro-4-{4-[3-(1H-indol-3-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(1H-indol-3-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- 25 (S)-N-[3-(3-Fluoro-4-{4-[3-(1H-indol-3-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thiourea;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(furan-2-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(furan-2-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- 30 (S)-N-[3-(3-Fluoro-4-{4-[3-(furan-2-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thiourea;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-3-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

- (S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-3-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-4-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 5 (S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-4-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-4-yl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;
- (S)-N-[3-(3-Fluoro-4-{4-[3-phenyl-propanoyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 10 (S)-N-[3-(3-Fluoro-4-{4-[3-phenyl-propanoyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(4-fluorophenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 15 (S)-N-[3-(3-Fluoro-4-{4-[3-(4-fluorophenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(4-fluorophenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(4-fluorophenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thiocarbamate;
- 20 (S)-N-[3-(3-Fluoro-4-{4-[3-phenyl acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-phenyl acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- 25 (S)-N-[3-(3-Fluoro-4-{4-[3-phenyl acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(4-methoxyphenyl) acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(4-methoxyphenyl) acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- 30 (S)-N-[3-(3-Fluoro-4-{4-[3-(4-methoxyphenyl) acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(4-acetoxyphenyl) acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

- (S)-N-[3-(3-Fluoro-4-{4-[3-(4-acetoxyphenyl) acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(4-acetoxyphenyl) acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thiourea;
- 5 (S)-N-[3-(3-Fluoro-4-{4-[3-furan-3-yl-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(3,4-difluorophenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-{4-[3-(3,4-difluorophenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- 10 (S)-N-[3-(3-Fluoro-4-{4-[3-(3,4-difluorophenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- Methanesulfonic acid 4-[3-(4-{4-[5-(acetyl aminomethyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenyl} piperazin-1-yl)-3-oxo-propenyl]-phenyl ester;
- 15 (S)-N-[3-(3-Fluoro-4-{4-[3-(4-methylsulfanyl-phenyl)-acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(4-{4-[3-(3,4-dihydroxyphenyl)-acryloyl]-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(4-{4-[3-biphenyl-4-yl-acryloyl]-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 20 (S)-N-[3-(4-{4-but-2-enoyl-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(4-{4-acryloyl-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 25 (S)-N-[3-(3-Fluoro-4-{4-[2-methylacryloyl-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(4-{4-[3-(4-benzyloxy-phenyl)-acryloyl]-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl] thiourea;
- (S)-N-[3-(4-{4-[3-(4-nitrophenyl)-acryloyl]-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 30 Carbonic acid-1-{4-[3-(4-{4-[5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenyl}-piperazin-1-yl)-3-oxo-propenyl]-phenoxy}-ethyl ether cyclohexyl ester;
- (S)-N-[3-(4-{4-[3-(4-aminophenyl)-acryloyl]-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

- (S)-N-[3-(4-{4-[3-(3,4-diacetoxy-phenyl)-acryloyl]-piperazin-1-yl}-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(4-{4-[3-benzo[1,3]-dioxol-5-yl acryloyl]-piperazin-1-yl}-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl] thiocarbamate;
- 5 (S)-N-[3-(3-Fluoro-4-[4-(4-oxo-4-phenyl-but-2-enoyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-[4-(4-(4-methoxyphenyl)-4-oxo-but-2-enoyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-[4-(4-(4-methoxyphenyl)-4-oxo-but-2-enoyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- 10 (S)-N-[3-(4-[4-(4-(4-acetylaminophenyl)-4-oxo-but-2-enoyl)-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-[4-(4-(4-acetylaminophenyl)-acryloyl)-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 15 (S)-N-[3-(3-Fluoro-4-[4-(3-cyclohexyl)-acryloyl-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- Acetic acid-2-(4-{4-[5-(acetylaminomethyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenyl}[-piperazinyl-1-carbonyl-7-amino-3-oxo-5-thia-1-aza-bicyclo-[4.2.0]-oct-2-en-3-yl-methyl ester];
- 20 2,2-Dimethyl-propanoic acid-4-(3-(4-{4-[5-(acetylaminomethyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenyl}piperazinyl-1-yl)-3-oxo-propenyl] phenyl ester;
- Carbonic acid-1-{4-[3-(4-{4-[5-(acetylaminomethyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenyl}[-piperazinyl-1-yl]-3-oxo-propenyl] phenyl ester};
- (S)-N-[3-(3-Fluoro-4-[4-(3-(5-nitrofuran-2-yl)-acryloyl-piperazin-1-yl]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 25 (S)-N-[3-(3-Fluoro-4-[4-(6-methoxy-1-oxo-1,2,3,4 tetrahydronaphthalen-2-yl methyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-[4-(1-oxo-1,2,3,4 tetrahydronaphthalen-2-yl methyl)-piperazin-1-yl]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 30 (S)-N-[3-(3-Fluoro-4-[4-(5-methoxy-1-oxo-indan-2-yl-methyl)-piperazin-1-yl]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-[4-(2-oxo-cyclohexylmethyl)-piperazin-1-yl]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;


- (S)-N-[3-(3-Fluoro-4-[4-(6-methoxy-1-oxo-1,2,3,4 tetrahydronaphthalen-2-yl methyl)-piperazin-1-yl]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- (S)-N-[3-(3-Fluoro-4-[4-(5-methoxy-1-oxo-indan-2-yl-methyl)-piperazin-1-yl]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- 5 (S)-N-[3-(3-Fluoro-4-[4-(1-hydroxyimino-6-methoxy-1,2,3,4 tetrahydronaphthalen-1-yl methyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-[4-(4-methyl-1-oxo-1,2,3,4 tetrahydronaphthalen-2-yl methyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl] thioacetamide;
- Trans-(S)-N-(3-{3-Fluoro-4-[4-(3-1H-pyrrol-2-yl-acryloyl)-piperazin-1-yl]-phenyl}-2-oxo-oxazolidin-5-yl-methyl)acetamide.
- 10 Cis-(S)-N-(3-{3-Fluoro-4-[4-(3-1H-pyrrol-2-yl-acryloyl)-piperazin-1-yl]-phenyl}-2-oxo-oxazolidin-5-yl-methyl)acetamide.
- (S)-5-[3-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolin-3-yl]-2-fluoro-phenyl}-piperazin-1-yl)-3-oxo-propenyl]-furan-2-carboxylic acid sodium salt
- 15 (S)-5-[3-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolin-3-yl]-2-fluoro-phenyl}-piperazin-1-yl)-3-oxo-propenyl]-furan-2-carboxylic acid.
- (S)-N-[3-(3-Fluoro-4-{4-[3-(5-hydroxymethyl-furan-2-yl)-acryloyl]-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide.
- (S)-N-[3-(3-Fluoro-4-{4-[3-(4-methanesulfonyl-phenyl)-acryloyl]-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide.
- 20 (S)-4-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl}-piperazin-1-yl)-4-oxo-but-2-enoic acid.
- (S)-N-[3-(3-Fluoro-4-{4-[3-(5-formyl-furan-2-yl)-acryloyl]-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide.
- 25 (S) -Acetic acid-5-[3-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolin-3-yl]-2-fluoro-phenyl}-piperazin-1-yl)-3-oxo-propenyl]-furan-2-yl methyl ester.
- (S)-4-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl}-piperazin-1-yl)-4-oxo-but-2-enoic acid sodium salt.
- (S)-N-[3-(3-Fluoro-4-{4-[3-(5-methyl-furan-2-yl)-acryloyl]-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide.
- 30 (S)-N-[3-(3-Fluoro-4-{4-propynoyl-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- (S)-N-[3-(3-Fluoro-4-{4-(4-hydroxy-but-2-enoyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;



- (S)-N-[3-(3-Fluoro-4-{4-(4-bromo-but-2-enoyl)-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
- 2-[4-(4-{5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl}-2-fluorophenyl)-piperazin-1-carbonyl]-3-phenyl-acrylic acid methyl ester;
- 5 2-[4-(4-{5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl}-2-fluorophenyl)-piperazin-1-carbonyl]-3-phenyl-acrylic acid;
- 2-[4-(4-{5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl}-2-fluorophenyl)-piperazin-1-carbonyl]-3-furane acrylic acid methyl ester;
- 2-[4-(4-{5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl}-2-fluorophenyl)-piperazin-1-carbonyl]-3-furane-acrylic acid;
- 10 12. A pharmaceutical composition, which comprises a compound as defined in claim 11, and a pharmaceutically acceptable carrier, diluents or excipients or solvate.
13. A pharmaceutical composition as claimed in claim 12, in the form of a tablet, capsule, powder, granules, syrup, solution or suspension.
- 15 14. A method for treating bacterial infections, psoriasis or arthritis in mammals comprising administering a therapeutically acceptable amount of compounds of claim 11, or a therapeutically acceptable salt or prodrug thereof.
15. The method as claimed in claim 14 wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.
- 20 16. A method for treating toxicity due to chemotherapy in a patient comprising administering a therapeutically acceptable amount of compounds of claim 11, or a therapeutically acceptable salt or prodrug thereof.
17. The method as claimed in claim 16 wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.
- 25 18. A medicine for treating bacterial infections, psoriasis, arthritis in mammals comprising administering a therapeutically acceptable amount of compounds described in any preceding claims, or a therapeutically acceptable salt or prodrug thereof.
19. A medicine for treating toxicity due to chemotherapy in a patient comprising administering a therapeutically acceptable amount of compound described in any preceding claims, or a therapeutically acceptable salt or prodrug thereof.
- 30 20. The medicine as claimed in any preceding claims wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.

21. A process for the preparation of a compound of formula (I) as claimed in claim 1, where all symbols are as defined earlier, and including their derivatives, their analogs, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, which comprises:


- 5 i. by reacting a compound of formula (1a) with a compound of formula (1b)



where all symbols are as defined earlier and R represents OH, halide or an acyloxy group, to yield compound of formula (I).

10


- ii) by reacting a compound of formula (1c) with a compound of formula (1b)



where all symbols are as defined earlier, to yield compounds of formula (I).

15

- iii) Reacting a compound of formula (1m) with a compound of formula (1b) to give compound of formula (1n):




where all symbols are as defined earlier; The compound (1n) represents compound of formula (I), where Y represents G<sub>3</sub> as defined in claim 1.


20

22. A process of converting compounds of formula (I) to further compounds of formula (I), which comprises:


a) reacting of a compound of formula (1a) with a compound of formula (1d) to yield (1e),




b) Converting a compound of formula (1e) to (1f) where L represents a leaving group such as -OMs, -OTs, halides etc.




c) Converting compound (1f) to (1g)




d) Converting compound (1g) to (1h)



e) Converting (1h) to (1i)




f) Converting (1i) to (1j)



5 Alternatively,


g) Converting compound (1i) to (1k)



10

Alternatively

h) Converting compound (1i) to (1l)



where all symbols are as defined earlier and compounds of formula (Ie), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), represent compounds of formula (I), and W represents OH, N<sub>3</sub>, NH<sub>2</sub>, NCS, NHCSR<sub>7</sub>, NHCSSR<sub>7</sub>, NHCSOR<sub>7</sub> respectively, and Y represents G<sub>2</sub> with X=O.

5

10

15

20

25

30

35

40